TECX

Tectonic Therapeutic, Inc. Common Stock

19.54 USD
+0.05
0.26%
At close Apr 23, 4:00 PM EDT
1 day
0.26%
5 days
10.83%
1 month
-8.69%
3 months
-53.70%
6 months
-43.38%
Year to date
-57.23%
1 year
1,514.88%
5 years
38.98%
10 years
-37.37%
 

About: Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Employees: 51

0
Funds holding %
of 7,419 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

257% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 7

63% more capital invested

Capital invested by funds: $217M [Q3] → $355M (+$137M) [Q4]

40% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 15

35% more funds holding

Funds holding: 52 [Q3] → 70 (+18) [Q4]

3.4% more ownership

Funds ownership: 48.72% [Q3] → 52.11% (+3.4%) [Q4]

60% less funds holding in top 10

Funds holding in top 10: 5 [Q3] → 2 (-3) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$51
161%
upside
Avg. target
$76
289%
upside
High target
$101
417%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Mizuho
Uy Ear
29% 1-year accuracy
2 / 7 met price target
161%upside
$51
Outperform
Initiated
21 Apr 2025
Wells Fargo
Tiago Fauth
30% 1-year accuracy
8 / 27 met price target
417%upside
$101
Overweight
Maintained
21 Mar 2025

Financial journalist opinion

Positive
Seeking Alpha
14 hours ago
Tectonic Therapeutic: A Buy On Massive Opportunity Of TX45 In PH HFpEF
We initiate a Buy rating on Tectonic Therapeutic due to promising data for TX45. TX45 showed positive interim Phase 1b results, but the APEX Phase 2 trial with 180 patients will be crucial for validating its efficacy and safety. TX2100 targets hereditary hemorrhagic telangiectasia with promising preclinical data, aiming for a Phase 1 launch in late 2025 or early 2026.
Tectonic Therapeutic: A Buy On Massive Opportunity Of TX45 In PH HFpEF
Neutral
GlobeNewsWire
1 month ago
Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
WATERTOWN, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”), today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided an overview of recent business highlights.
Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
Positive
Seeking Alpha
2 months ago
Tectonic: Expansion Of TX45 Candidate Possible After Positive Interim Data
Positive interim results released from phase 1b study, using TX45 for the treatment of patients with pulmonary hypertension heart failure with preserved ejection fraction. Data from phase 1b study using TX45 for the treatment of patients with pulmonary hypertension heart failure with reduced ejection fraction, expected in 2nd half of 2025. In the 7 major markets, the heart failure market is expected to grow to $33.7 billion in 2032.
Tectonic: Expansion Of TX45 Candidate Possible After Positive Interim Data
Neutral
GlobeNewsWire
2 months ago
Tectonic Announces $185 Million Private Placement
WATERTOWN, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc.  (NASDAQ: TECX) (“Tectonic”), today announced that it has entered into a securities purchase agreement for a private investment in public equity financing (the “PIPE”) that is expected to result in gross proceeds of approximately $185.0 million.
Tectonic Announces $185 Million Private Placement
Neutral
GlobeNewsWire
2 months ago
Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), today announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate, TX45, a long-acting, Fc-relaxin fusion protein. The interim data showed that a single intravenous dose of TX45 resulted in meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”). In the trial, TX45 was well tolerated in patients with PH-HFpEF with no serious or severe adverse events.
Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF
Positive
Seeking Alpha
3 months ago
Tectonic Therapeutic: Protein Engineering Platform For GPCRs
Tectonic's lead asset, TX45, is a long-acting Fc-relaxin fusion protein to treat group 2 pulmonary hypertension, showing promise in early clinical trials. TX45's extended half-life and monthly dosing address limitations of native relaxin, positioning it as a potential best-in-class therapeutic. With favorable phase 1a data and ongoing phase 1b and 2 trials, Tectonic's TX45 could become a market leader, potentially attracting interest from potential biopharma acquirers.
Tectonic Therapeutic: Protein Engineering Platform For GPCRs
Neutral
GlobeNewsWire
4 months ago
Tectonic Therapeutic to Host KOL Event on the Unmet Need in Group 2 PH-HFpEF and TX45 as a Potential Treatment on Thursday, December 12, 2024
WATERTOWN, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”) a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”), today announced it will host a virtual key opinion leader (KOL) event on Thursday, December 12, 2024 from 4:00 PM to 6:00 PM ET. To register, click here .
Tectonic Therapeutic to Host KOL Event on the Unmet Need in Group 2 PH-HFpEF and TX45 as a Potential Treatment on Thursday, December 12, 2024
Neutral
GlobeNewsWire
4 months ago
Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference
WATERTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (Tectonic), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that Alise Reicin, MD, President and Chief Executive Officer, will present at the Piper Sandler 36th Annual Healthcare Conference being held in New York on December 3-5, 2024.
Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference
Neutral
GlobeNewsWire
5 months ago
Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein
WATERTOWN, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”) a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”), today announced detailed results from the Phase 1a clinical trial of its lead asset, TX45, a long-acting, Fc-relaxin fusion protein. The poster will be presented at the American Heart Association (AHA) Scientific Sessions on November 16, 2024 from 3-4pm EST in Chicago, Illinois. Favorable topline results from the TX45 Phase 1a clinical trial were announced on September 19, 2024, along with the dose selection for the TX45 APEX Phase 2 trial that is currently underway in patients with PH-HFpEF.
Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein
Neutral
GlobeNewsWire
6 months ago
Tectonic Therapeutic to Present Phase 1a Data at AHA 2024
American Heart Association (AHA) poster to be presented on November 16, 2024 American Heart Association (AHA) poster to be presented on November 16, 2024
Tectonic Therapeutic to Present Phase 1a Data at AHA 2024
Charts implemented using Lightweight Charts™